Braver Wealth Management Lowers stake in Amgen (AMGN)

Amgen (AMGN) : Braver Wealth Management reduced its stake in Amgen by 3.4% during the most recent quarter end. The investment management company now holds a total of 31,108 shares of Amgen which is valued at $4,993,456 after selling 1,094 shares in Amgen , the firm said in a disclosure report filed with the SEC on Jul 13, 2016.Amgen makes up approximately 0.83% of Braver Wealth Management’s portfolio.

Other Hedge Funds, Including , Capstone Asset Management Co reduced its stake in AMGN by selling 874 shares or 0.69% in the most recent quarter. The Hedge Fund company now holds 126,606 shares of AMGN which is valued at $20,322,795. Amgen makes up approx 0.60% of Capstone Asset Management Co’s portfolio.Creative Planning boosted its stake in AMGN in the latest quarter, The investment management firm added 3,503 additional shares and now holds a total of 67,175 shares of Amgen which is valued at $10,782,931. Amgen makes up approx 0.08% of Creative Planning’s portfolio.Pacwest Financial Management Inc reduced its stake in AMGN by selling 25 shares or 0.22% in the most recent quarter. The Hedge Fund company now holds 11,465 shares of AMGN which is valued at $1,840,362. Amgen makes up approx 1.12% of Pacwest Financial Management Inc’s portfolio.Triangle Securities Wealth Management reduced its stake in AMGN by selling 30 shares or 0.24% in the most recent quarter. The Hedge Fund company now holds 12,445 shares of AMGN which is valued at $2,004,890. Amgen makes up approx 1.48% of Triangle Securities Wealth Management’s portfolio.Raymond James Trust N.a. boosted its stake in AMGN in the latest quarter, The investment management firm added 8,185 additional shares and now holds a total of 36,838 shares of Amgen which is valued at $5,934,602. Amgen makes up approx 0.50% of Raymond James Trust N.a.’s portfolio.

Amgen closed down -0.35 points or -0.21% at $162.93 with 18,15,610 shares getting traded on Monday. Post opening the session at $163.82, the shares hit an intraday low of $162.79 and an intraday high of $164 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.